In a 36-year-old woman with hyperandrogenism (elevated testosterone) and polycystic ovary syndrome, what are the possible causes and recommended treatment options?

Elevated Testosterone in PCOS: Causes and Treatment

In a 36-year-old woman with PCOS and elevated testosterone, the hyperandrogenism is most commonly caused by gonadotropin-dependent functional ovarian hyperandrogenism (the primary mechanism in PCOS itself), and first-line treatment should be hormonal contraceptives (combined oral contraceptives) to suppress androgen production and manage symptoms, with lifestyle modification (calorie-restricted diet and exercise) if overweight or obese. 1

Understanding the Cause

The elevated testosterone in your patient is intrinsic to PCOS pathophysiology:

• Functional ovarian hyperandrogenism is the major source of excess androgens in the majority of PCOS cases, driven by gonadotropin-dependent mechanisms 1
• Mild ACTH-dependent functional adrenal hyperandrogenism may accompany ovarian sources or, less commonly, be the primary driver 1
• Insulin resistance plays a central role, creating a vicious cycle with hyperandrogenism that drives metabolic dysfunction, visceral adiposity, hepatic steatosis, and skeletal muscle dysfunction 2

Red Flags to Exclude

Before attributing hyperandrogenism solely to PCOS, rule out:

• Androgen-secreting tumors (ovarian or adrenal) if testosterone >150 ng/dL or DHEA-S >700 μg/dL 3
• Rapid onset or virilization (clitoromegaly, deepening voice, male-pattern baldness) suggests tumor 4, 3
• Nonclassic congenital adrenal hyperplasia (present in <5% of hyperandrogenic women) 1
• Cushing's syndrome or other secondary causes 3

Treatment Algorithm

First-Line Therapy

Combined oral contraceptives (COCs) are the cornerstone 5, 1:

• Suppress gonadotropin-driven ovarian androgen production
• Improve menstrual regularity, hirsutism, and acne
• Use the lowest effective estrogen dose 6
• Expect hirsutism improvement after 6-8 months (acne responds faster at 3 months) 7
• Caution: COCs provide limited metabolic benefits and don't address insulin resistance 2

Lifestyle modification (if overweight/obese) 5:

• Calorie-restricted diet and exercise
• Weight loss improves both symptoms and endocrine profile 8
• This is metabolic-focused therapy that disrupts the hyperandrogenism-insulin resistance cycle 2

Second-Line: Add Antiandrogen

If patient-important hirsutism persists after ≥6 months of COC monotherapy, add an antiandrogen 1:

• Spironolactone (aldosterone antagonist/androgen receptor blocker)
• Finasteride (5α-reductase inhibitor)
• Must use with effective contraception (teratogenic) 1

Metformin Consideration

Metformin is an option when targeting metabolic abnormalities 5:

• Improves insulin resistance, hyperandrogenemia, and menstrual regularity
• More beneficial in adolescents than adults with PCOS 5
• Consider if glucose intolerance or diabetes risk is present
• Does not directly lower androgens as effectively as COCs

Avoid These Therapies

• Thiazolidinediones: Removed (troglitazone) or restricted (rosiglitazone) due to hepatic/cardiovascular toxicity; pioglitazone linked to bladder cancer 5
• Statins: Only use if patient meets standard cardiovascular indications (teratogenic, Pregnancy Category X) 5
• GnRH agonists: Reserve only for severe hyperandrogenemia (e.g., ovarian hyperthecosis) unresponsive to COCs and antiandrogens 1
• Glucocorticoids: Not recommended for PCOS-related hyperandrogenism 1

Treatment Timeline Expectations

• Acne: Improvement at 3 months 7
• Hirsutism: Observable improvement at 6-8 months, maximal at 9 months (due to 4-month hair growth cycle) 1, 7
• Androgenic alopecia: Slowest response, requires 12-18 months if responsive at all 7
• Trial period: Give any pharmacological therapy ≥6 months before changing dose or adding medication 1

Adjunctive Cosmetic Management

Combine medical therapy with cosmetic treatments for hirsutism 7:

• Topical eflornithine hydrochloride (follicle ornithine decarboxylase inhibitor)
• Short-term: shaving, depilation, plucking, threading, waxing, bleaching
• Long-term: electrolysis, laser therapy, intense pulsed light

Key Clinical Pitfall

The most common error is treating hyperandrogenism with COCs alone without addressing metabolic dysfunction. COCs suppress androgens and alleviate symptoms but provide minimal metabolic benefits 2. In a 36-year-old with PCOS, assess for insulin resistance, impaired glucose tolerance, dyslipidemia, and cardiovascular risk—these require metabolic-focused interventions (lifestyle modification, metformin) that break the hyperandrogenism-insulin resistance cycle 2.